Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
Authors:
Open Access
- 13 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Bioinformatics
- Vol. 2
Abstract
Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE.Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were completed through AutoDock Vina and PyMOL software for visualization.Result: A total of 292 potential targets of IGU, 6501 related disease targets of SLE, and 114 cross targets were screened from the aforementioned database. Network topology analysis identified 10 hub targets, such as CASP3, AKT1, EGFR, MMP9, and IGF1. GO enrichment analysis mainly focuses on the negative regulation of the apoptotic process and signal transduction. KEGG enrichment analysis illustrated that the PI3K-AKT signaling pathway, MAPK signaling pathway, and FoxO signaling pathway might play a significant role in the pharmacological mechanisms of IGU act on SLE. Molecular docking confirmed that the IGU ligand had strong binding activity to the hub targets.Conclusion: This study based on network pharmacology and molecular docking validation preliminarily revealed the protein targets affected by IGU acting on SLE through, and explored potential therapeutic mechanism role of IGU in SLE treatment by multi pathways.Keywords
Funding Information
- Sanming Project of Medicine in Shenzen Municipality
- Science and Technology Planning Project of Shenzen Municipality
This publication has 47 references indexed in Scilit:
- Altered AKT1 and MAPK1 Gene Expression on Peripheral Blood Mononuclear Cells and Correlation with T-Helper-Transcription Factors in Systemic Lupus Erythematosus PatientsMediators of Inflammation, 2012
- Multicenter, randomized, double‐blind, controlled trial of treatment of active rheumatoid arthritis with T‐614 compared with methotrexateArthritis Care & Research, 2009
- Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cellsClinical and Experimental Immunology, 2009
- T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritisArthritis Research & Therapy, 2008
- Expanding the Mind: Insulin-Like Growth Factor I and Brain DevelopmentEndocrinology, 2008
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTORProceedings of the National Academy of Sciences, 2008
- Critical roles of the PI3K/Akt signaling pathway in T cell developmentImmunology Letters, 2008
- Network pharmacologyNature Biotechnology, 2007
- Immunohistochemical Expression of Activated Caspase-3 as a Marker of Apoptosis in Glomeruli of Human Lupus NephritisAmerican Journal of Kidney Diseases, 2006
- Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID miceRheumatology, 2003